Go to Page # Page of 24

Pharmaceutical and Biotechnology R&D: Technological Performance Implications

 Jongwook Kim
  15th-Feb-2017
Description: Why biotechnology alliances?:- It is difficult to measure alliance performance, particularly in R&D alliances. Biotechnology alliances provides an empirical context where a fairly objective indicator of alliance performance exists: Because of FDA regulations, information about intermediate stages in drug development are made public.Biotechnology industry:- Small biotechnology R&D firms usually have capabilities in product R&D activities (upstream activities). Larger pharmaceutical firms (and some established biotechnology firms) supply capabilities in commercialization activities (downstream activities, i.e., manage the regulatory process, large-scale manufacturing, marketing & distribution, etc.).
Views: 726
Domain: Medical
Category: Biotech/Pharma
Contributing Organization: KLIC
 ‐ More of their Presentations
LithoVision 2018
Contents:
Pharmaceutical-Biotechnology R&D:
Technological Performance Implications

JONGWOOK KIM
Western Washington University
College of Business and Economics

Introduction: Research question


How do different governance mechanisms – both formal
and informal – impact alliance performance?






How do formal governance mechanisms that seek to
mitigate informat ... See more

Recent Presentations

Jefferies LLC.
16 January, 2018

Design to value in medical devices

If medical device companies want to continue to make money as prices face continued pressure, their only option is to take cost out. This comment from the head of procurement at a

...
15 January, 2018
Web Japan
14 January, 2018